Drug intelligence / Profile preview

Tetragalacturonic acid hydroxymethylester

Development stage: Unknown
Modality: Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
Administration: Topical

Overview

Tetragalacturonic acid hydroxymethylester is a linear tetrasaccharide composed of four hydroxymethyl alpha-D-galacturonosyl residues linked sequentially (1→4). It is derived from apple pectin and functions as a local antihemorrhagic agent, with research suggesting it may inhibit fibrinolysis in vitro. Although it has been studied for its potential to stop bleeding, particularly by acting as an antifibrinolytic, it has not been used clinically. Its primary role is as a hematologic agent within the class of local hemostatics[1][3][4].

Other names: tetragalacturonic acid hydroxymethylester

Targets

PLAU (uPA)

Beyond the preview

Go deeper on Tetragalacturonic acid hydroxymethylester.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tetragalacturonic acid hydroxymethylester.

Explore the full profile